05-11-2012, 11:05 AM
Join Date: Oct 2010
Location: Los Angeles area
L-DOPA Amide pending patent
Has there been other info about this?
It sounds very promising.
7-2006-138 | L-DOPA Amide Derivatives for Treating Parkinson’s Disease
Atlas Daphne, HUJI, Faculty of Science, The Alexander Silberman Institute for Life Sciences
Novel treatment for Parkinson’s disease overcomes “on-off” phenomenon
Concept proven, in vivo human models
Pending patent application in, Europe, US and Israel (PCT publication № WO2004/069146)
Increases the endogenous level of dopamine to alleviate the motor complications of Parkinson’s disease and to delay the onset of the symptoms from the dramatic decrease in dopamine
Formulated for buccal, oral, sub-lingual, parenteral, intranasal, intramuscular, intravenous, subcutaneous, intraduodenal or rectal administration
Provides a pharmaceutical preparation for the treatment of patients suffering from PD comprising a composition of L-Dopamide
A water-soluble compound could be applied f for rescue therapy. An advantage over the insoluble L-DOPA
Involves an essential structural change to make L-DOPA more soluble and resistant to DOPA Decarboxylase
Administrable without Carbidopa due to resistance to DOPA-decarboxylase
L-Dopamide is slowly hydrolyzed to L-DOPA because it is resistance to DOPA decarboxylase
Slow release addresses the on/off phenomenon of Parkinson’s
Degrades to natural products
Addresses the need for more effective therapy for Parkinson’s disease using a more sustained level of dopamine
Oral application in animal model showed longer duration > 40% over L- DOPA.
Higher efficiency as a proof of concept in experiments made side by side with L-DOPA
PK studies available
Ready for toxicology studies.
Granted US 8,048,926